409
Participants
Start Date
January 28, 2013
Primary Completion Date
December 30, 2015
Study Completion Date
December 30, 2015
Mavrilimumab 100 mg
Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years
Research Site, Ciudad Autonoma Buenos Aires
Research Site, Ciudad Autonoma de Buenos Aire
Research Site, Rosario
Research Site, San Miguel de Tucumán
Research Site, Plovdiv
Research Site, Sofia
Research Site, Santiago
Research Site, Viña del Mar
Research Site, Barranquilla
Research Site, Bruntál
Research Site, Jihlava
Research Site, Ostrava - Trebovice
Research Site, Prague
Research Site, Uherské Hradiště
Research Site, Zlín
Research Site, Tallinn
Research Site, Cologne
Research Site, Magdeburg
Research Site, Athens
Research Site, Larissa
Research Site, Baja
Research Site, Balatonfüred
Research Site, Budapest
Research Site, Debrecen
Research Site, Ashkelon
Research Site, Kfar Saba
Research Site, Petah Tikva
Research Site, Mérida
Research Site, Gdynia
Research Site, Grodzisk Mazowiecki
Research Site, Katowice
Research Site, Krakow
Research Site, Wroclaw
Research Site, Barnaul
Research Site, Kazan'
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Yaroslavl
Research Site, Belgrade
Research Site, Niška Banja
Research Site, Bratislava
Research Site, Durban
Research Site, Barcelona
Research Site, Málaga
Research Site, Santiago de Compostela
Research Site, Donetsk
Research Site, Kharkiv
Research Site, Kiev
Research Site, Lutsk
Research Site, Vinnytsia
Research Site, Edinburgh
Research Site, London
Lead Sponsor
MedImmune LLC
INDUSTRY